Bedaquiline treatment reaches patients in Uganda, Swaziland, Philippines, and Georgia

The Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program works with countries to adopt new medicines and regimens, such as bedaquiline for MDR-TB, using a systems strengthening approach that engages stakeholders, builds on existing systems or establishes new ones where appropriate, strengthens human resources via trainings, improves the distribution chain for new TB […]

New TB Medicines & Regimens eCourse

Thanks to a bigger push for innovation as part of the End TB strategy, new medicines—bedaquiline (Sirturo™) and delamanid (Deltyba™)—are now available to treat MDR-TB and XDR-TB with a novel short-course regimen. However, countries and partners have been slow to use these drugs, and many health workers lack expertise in prescribing them. Many health facilities […]

SIAPS Launches Innovative Digital Health Tool in Georgia to Monitor Adverse Drug Reactions

In April 2015, the US Agency for International Development (USAID) and Janssen Therapeutics officially launched the bedaquiline donation initiative. As part of this initiative, Janssen committed to providing bedaquiline at no cost to 30,000 patients with multidrug-resistant tuberculosis (MDR-TB) over a four-year period. Bedaquiline is the first anti-TB medicine to be approved by the U.S. Food […]

Bedaquiline Treatment Reaches 200 Patients in Georgia

Georgia is one of the first countries to benefit from the USAID‑Janssen Therapeutics bedaquiline (BDQ) donation program. Along with delamanid, BDQ is one of only two new TB medicines released to the market in over 40 years. These medicines are being used for the treatment of MDR-TB patients, as well as TB patients who have […]

On the Market: Interviews on Bedaquiline Use

In April 2015, USAID and Janssen Therapeutics officially launched the bedaquiline (BDQ) donation initiative, under which Janssen committed to providing free BDQ to 30,000 patients with multidrug-resistant tuberculosis (MDR-TB) over a four-year period. Along with delamanid, BDQ is one of only two new TB medicines released to the market in over 40 years. These medicines […]

Celebrating Successes and Lessons Learned in Swaziland: Steps Toward Strong Systems

For the recognition of World TB Day on March 24, 2016, the USAID-funded Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program team launched a blog post highlighting successes and lessons learned in Swaziland. The blog recounts the history of bedaquiline entrance into the market, the potential challenges surrounding this new TB drug, and […]

Georgia: First Recipient of Free Bedaquiline

The launch of the new bedaquiline donation program in Georgia was marked by an event at the National Center for TB and Lung Diseases in Tbilisi on October 13. Read More > From left to right: The USAID Acting Mission Director in Georgia, Thomas R. Morris, Executive director of the National Center for TB and lung diseases […]